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Recent additions of succinate dehydrogenase (SDH) and 
hereditary leiomyomatosis and renal cell cancer (HLRCC, 
associated) fumarate hydratase (FH)-deficient renal cell 
carcinomas (RCC) to the 2016 WHO Classification of 
Renal Tumours (1) have highlighted an evolving need for 
the distinction between renal cancer subtypes. Differences 
in molecular characterisation, clinical phenotypes, and 
therapeutic responses (1-3) further corroborates this 
paradigm shift and strongly points towards the development 
of subtype-specific management (3). SDH and FH-
deficient RCCs are rare tumours strongly associated 
with hereditary neoplastic syndromes and early-onset 
(2,4,5). FH-deficient RCCs are highly aggressive tumours 
associated with poor patient prognosis (2,3,6), whereas 
SDH-deficient RCCs are phenotypically more variable, 
but also known to exhibit aggressive disease behaviour 
(7-9). Whilst localised RCCs (regardless of subtype) 
are usually managed surgically (5,7,10), in advanced/ 
metastatic RCCs where systemic therapies are the mainstay 
of management (7,10), the majority of clinical trials that 
provide the basis for these guidelines are centred around 
clear cell RCC (11). Limited and/or no data is available 
to guide management of metastatic SDH-deficient RCC 
and, in particular, FH-deficient RCC (5,7). Furthermore, 
there is a lack of consensus as to the follow-up regime of 
patients with resected sporadic RCCs, and little evidence 
on how to observe SDH- or FH-deficient RCCs (7). 
Therefore, logic prevails on the strong emphasis placed on 
improving the accurate detection and diagnosis of these rare 
subtypes (9,12-16) to discern the phenotypic features more 
comprehensively and improve patient stratification in the 
evolving era of precision-based medicine.
Inactivating mutations rendering SDH and FH enzyme 
activity absent lead to the accumulation of succinate and 
fumarate respectively, which are bona fide oncometabolites 
that have pro-oncogenic capabilities such as the induction 
of protein modifications, aggressive tumour phenotypes, 
and epigenetic modulation (17,18). In particular, fumarate 
accumulation was shown to bind reactive thiol residues of 
proteins inducing a post-translational modification called 
succination (15,19). Of note, succinated proteins can be 
detected using antibodies against succinated cysteine 
residues (anti-2SC). In the manuscript recently published 
in Human Pathology, Gupta and colleagues (20) capitalise 
on this unique oncometabolite-associated trait and used 
immunohistochemistry (IHC) to probe SDHA/SDHB and 
FH/2SC for the detection of SDH and FH-deficient RCCs 
in a large historical panel of resected renal tumour subtypes 
(n=1,009). 
The authors used qualitative scoring [i.e. positive (+) or 
negative (−) comparative to an internal positive control] 
for SDHA, SDHB, and FH staining. Positive 2SC (2SC+) 
staining was determined based on a previous study that 
correlated an intensity rating and staining pattern of 2SC 
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with molecular analyses of FH mutations in RCC tissues (12). 
Tissue sections with abnormal IHC staining underwent 
pathological review using the WHO 2016 classification and 
cases were clinically correlated with patient records. Overall, 
three cases of SDH-deficient RCCs (SDHA+/SDHB−) 
were identified, and were all tumours originally diagnosed 
as oncocytomas (1.1%, n=273). Retrospective review of 
these tumours identified cardinal histological features in 
keeping with SDH-deficient RCC. Clinically, these patients 
presented with localised tumours (stage pT2 or lower) with 
no disease recurrence or adverse outcomes reported on 
follow up. Four cases of FH-deficient RCC were identified 
in a subset of tumours stained for FH/2SC (n=730). Two 
cases were identified in the papillary RCC cohort (0.5%, 
n=400), and 2 cases in the unclassified RCC cohort (4.4%, 
n=46). Characteristic absence of FH staining coupled with 
positive 2SC staining (FH−/2SC+) was reported in 3 cases, 
whereas one case (papillary RCC) exhibited retained FH 
expression with positive 2SC staining (FH+/2SC+). These 
tumours exhibited a highly aggressive phenotype with three 
patients developing metastatic disease, and in all four cases 
proved fatal. Unfortunately, confirmatory SDH/FH genetic 
analyses were not provided in this study.
This study reiterates the rarity of SDH- and FH-deficient 
RCC subtypes, and underlines some of the important 
caveats related to aberrant/indeterminate IHC staining 
and morphological heterogeneity of these rare subtypes. 
Although all 3 cases of SDH-deficient RCCs were detected 
in the oncocytoma cohort, the original diagnosis of these 
cases occurred between 1970 to 2012, before the addition of 
SDH-deficient RCC to the WHO 2016 Classification (1). 
It is likely that as awareness of these rare subtypes gains 
traction, the identification of the associated cardinal 
morphological features will lead to increased detection 
and diagnosis, which would be in keeping with this study’s 
pathological review reporting classic morphology consistent 
with SDH-deficient RCC in all 3 cases. Although it is 
possible that detecting classic morphological SDH-deficient 
RCC may be sufficient without IHC, the presence of variant 
histology has been previously reported for SDH-deficient 
RCC (8,21). In addition, this study identified 2 cases of 
FH-deficient RCCs of unclassified morphology. Both cases 
had highly aggressive disease behaviour in keeping with 
FH-deficient RCC. One patient had early onset of disease 
(22 years old) and in both cases, presented with locally 
advanced disease with subsequent metastatic spread, 
suggesting the clinical phenotype may remain consistent 
despite variant histology.
A limitation to this study is the lack of confirmatory 
molecular analyses to substantiate the authors’ claims. 
In the case of aberrant FH+/2SC+ staining, the authors 
suggested the possibility of dysfunctional FH protein 
in FH-deficient RCC, accounting for the retained FH 
expression on IHC. This hypothesis was backed by the 
authors reporting a separate case of a HLRCC patient 
harbouring a FH germline mutation exhibiting FH+/2SC+ 
staining on IHC. However, previous similar studies coupled 
with molecular analyses were able to identify cases of 
aberrant FH+/2SC+ staining with wildtype FH expression, 
as well as with FH mutations (14,22). We agree with the 
authors in that concurrent use of 2SC with FH staining 
is essential for the detection of FH-deficient RCCs, 
furthermore, aberrant staining patterns crucially need to be 
validated with FH molecular analysis before confirmation 
of disease. Of note, degradation of tissue specimens in this 
study posed a major issue in performing crucial molecular 
analyses and highlights a need for better technical methods 
in ensuring suitable sample preservation for multiple lines 
of testing. Other metabolic markers that exploit these 
unique oncometabolite-associated properties also show 
promise in detecting FH-deficient RCC. In pre-clinical 
models of FH loss, consistently elevated levels of urinary 
argininosuccinate as a result of fumarate-induced urea cycle 
metabolic reprogramming (23), as well as observed cellular 
accumulation of fumarate, 2SC and succinated proteins 
such as succinic-GSH (24,25), marks their potential as 
biomarkers for the detection of FH-deficient RCCs in 
tumour tissue and bodily fluids. A combination of these 
inexpensive, relatively straightforward detection methods 
that are highly specific to FH-deficiency may by the way 
forwards for improving detection and diagnosis of this 
aggressive subtype.
Overall, this study by Gupta and colleagues highlights 
the potential of IHC to be used as an adjunctive tool in the 
diagnosis of rare RCC subtypes, which is invaluable given 
the evidence for these rare subtypes to masquerade behind 
variant histology. Given that IHC is routinely established in 
clinical practice to assist the diagnosis of renal tumours (26), 
it would be relatively straightforward to add SDHA/B 
and FH/2SC staining to the IHC panel for clinical use to 
improve detection of these rare and aggressive subtypes. As 
highlighted, the ramifications of optimising detection of 
these subtypes are multi-fold. Detection will affect patients 
presenting with both localised and advanced disease, it will 
improve our knowledge of these poorly understood cohorts, 
and as both RCC subtypes are strongly associated with 
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hereditary syndromes, it will have important implications for 
genetic testing for the patient and their relatives. In particular, 
diagnosis of aggressive FH-deficient RCC at renal biopsy or 
resection of a localised tumour will improve stratification of 
patients into more intensive follow-up regimes (5), whereas 
in the advanced setting, it will enable stratification of patients 
into appropriate clinical trials that will ultimately enable data 
to be gathered for improving systemic and targeted therapies 
as well as guidelines for these cohorts, which would be in 
keeping with the climate directed towards subtype-specific 
management. However, with a very low incidence of SDH- 
and FH-deficient RCCs detected in this and previous similar 
studies (13,14,16,22), the question to debate is whether or 
not it would be logical and/or cost-effective to screen the 
entire RCC cohort to detect a few cases of SDH- or FH-
deficient RCC. Perhaps, it is in these cases that physicians 
and pathologists use their clinical acumen in aligning variant 
histology with a suspicious clinical history e.g., family or 
personal history of associated cancer phenotypes, early onset 
of disease, clinically aggressive phenotype etc, that may really 
serve in increasing the detection of these tumours within 
variant RCC subtypes. 
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